MENU

MNPR Stock Monopar Therapeutics (MNPR, $37.49) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 14, 2025

A.I.dvisor
at Tickeron.com
Loading...
MNPR - Monopar Therapeutics Inc
MACD signal
Bullish Trend
Odds of UP Trend
Tickeron
MACD signal
Price: $37.49
Daily change: +$2.6 (+7.45%)
Daily volume: 20K
Capitalization: $229.2M
Industry: Biotechnology
This is a Bullish indicator signaling MNPR's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 51 similar cases where MNPR's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

MNPR in upward trend: price expected to rise as it breaks its lower Bollinger Band on April 04, 2025

MNPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 40 cases where MNPR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 17, 2025. You may want to consider a long position or call options on MNPR as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MNPR just turned positive on April 14, 2025. Looking at past instances where MNPR's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

MNPR moved above its 50-day moving average on April 14, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MNPR advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for MNPR moved out of overbought territory on March 21, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The 10-day moving average for MNPR crossed bearishly below the 50-day moving average on April 03, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MNPR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MNPR entered a downward trend on April 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MNPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.398) is normal, around the industry mean (13.444). P/E Ratio (0.000) is within average values for comparable stocks, (62.833). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.754). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (250.783).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MNPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
MNPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company, which engages in building a drug development pipeline of oncology therapeutics in late preclinical and clinical development stages

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1000 Skokie Boulevard
Phone
+1 847 388-0349
Employees
10
Web
https://www.monopartx.com